FDA advisers voted to add six peptides, including BPC-157 and TB-500, to the 503A Bulks List, potentially expanding compounding pharmacy access. The committee rejected one peptide. The recommendations are not final and require FDA action.
FDA advisers have recommended that six controversial peptides be added to the US 503A Bulks List, a move that could open the door to broader pharmacy compounding of these substances. The Pharmacy Compounding Advisory Committee PCAC voted in favor of BPC-157, KPV, TB-500, MOTS-C, epitalon, and semax during a two-day meeting held on 23 and 24 July 2026.
Emideltide was the only peptide considered that the committee rejected. These recommendations do not constitute FDA approval, and the agency is not required to follow the committee's advice. However, if the FDA ultimately makes a positive decision, state-licensed 503A compounding pharmacies would be permitted to use these substances in compounded medicines, subject to the standard requirements governing pharmaceutical compounding.
This development could have significant implications for the peptide supply chain. BPC-157, TB-500, and related compounds have built a substantial following among fitness and wellness consumers, despite limited human clinical evidence. These products are frequently marketed online for applications including tissue repair, recovery, anti-ageing, and weight management.
The FDA has previously raised concerns about several of these compounds. For example, its assessment of BPC-157 cites limited safety information and potential risks relating to immunogenicity, peptide-related impurities, and API characterisation. For TB-500, the agency has said it has identified no human exposure data for drug products containing the peptide and also highlighted potential risks associated with aggregation and impurities. Similar concerns have been raised around MOTS-C and semax.
For manufacturers and ingredient suppliers, the regulatory shift could create opportunities as well as new quality and compliance requirements. Peptide APIs can present specific manufacturing challenges, including controlling impurities and aggregation, maintaining product consistency, and managing immunogenicity risks. The FDA's 503A framework requires bulk substances used by compounders to meet applicable standards and be accompanied by a valid certificate of analysis. The agency advises compounders to scrutinise their bulk-drug suppliers thoroughly.
The committee's votes have been closely watched by the industry, as they could signal a change in direction following the FDA's earlier concerns about these substances. The outcome also highlights the widening gap between consumer demand for peptide therapies and the conventional drug-development pathway. While supporters argue that regulated compounding could bring greater oversight to a largely grey-market sector, critics continue to question whether the available evidence supports wider clinical use.
For the pharmaceutical manufacturing sector, the next step will be waiting for the FDA's official response. Until the agency takes its own action, the advisory committee's recommendations do not themselves make the six peptides FDA-approved medicines, nor do they automatically permit their use in compounding.
Peptides referenced: BPC-157, TB-500, MOTS-c, Epithalon, Semax.
Related reading: Compounded GLP-1 Drugs Spark Concern Among Doctors and FDA, Sun Pharma Launches Generic Semaglutide in South Africa, PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care, Compounded GLP-1 Drugs Raise Concerns Among Doctors and FDA.